Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Shuttle Pharma is a Delaware-incorporated discovery and development stage pharmaceutical company that has historically focused on radiation therapy–related oncology and now also owns the Molecule.ai AI platform for molecular discovery and early-stage drug development.
Through its Forms 8-K, Shuttle Pharma reports material events such as asset purchase agreements, private placements, consulting arrangements and changes to clinical programs. For example, 8-K filings describe the binding term sheet and subsequent asset purchase agreement under which a wholly owned subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Other 8-Ks detail a securities purchase agreement for a pre-funded warrant, settlement and winddown of Ropidoxuridine clinical trials, and communications related to Nasdaq listing requirements.
Shuttle Pharma’s registration statements on Form S-1 and S-1/A offer a broader business overview, including its origins as a radiation therapy–focused specialty pharmaceutical company, the development history of Ropidoxuridine, and a detailed description of the Molecule.ai platform’s architecture and functions. These filings also explain the terms of registered resales of shares issuable upon exercise of the pre-funded warrant and provide risk factor discussions relevant to a development-stage biotech and AI platform owner.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to quickly understand key points such as transaction structures, milestone-based consideration, changes in clinical strategy, and implications of listing compliance notices. Access to Form 4 insider transaction reports, when filed, and periodic reports like Forms 10-K and 10-Q, when available, helps investors track governance, capital structure and ongoing operations.
By consolidating Shuttle Pharma’s SEC filings and layering AI-generated explanations on top of the raw documents, this page is designed to make it easier to follow SHPH’s evolution as a company combining oncology development with AI-enabled molecular research infrastructure.
Shuttle Pharmaceuticals Holdings (SHPH)Form 3 reflecting beneficial ownership status as of 09/12/2025.
The filing shows 0 shares of common stock held directly and lists no derivative securities. This is an administrative disclosure of insider holdings and does not reflect a transaction.
Shuttle Pharmaceuticals Holdings (SHPH) director filed an initial Form 3 disclosing beneficial ownership as of 09/12/2025. The filing reports 0 shares of common stock beneficially owned and no listed derivative securities. It was filed by one reporting person in the capacity of director, indicating no equity holdings at the time of the event.
Shuttle Pharmaceuticals (SHPH) disclosed two material updates. On October 20, 2025, the company signed a binding term sheet to purchase substantially all assets and liabilities of 1542770 BC Ltd. (Molecule) for $10,000,000, payable over time in a mix of cash and SHPH common stock at the company’s determination and tied to milestones. Closing remains subject to definitive agreements, board approval, and due diligence.
Separately, on October 15, 2025, Theradex Systems, the company’s primary CRO, delivered a notice terminating the 2018 master agreement and demanding immediate payment of $1.091 million. The letter cites a contract provision allowing termination for material breach and states Services will cease if payment is not made within 30 days of the letter. Together, the prospective acquisition outlines a strategic transaction, while the CRO action introduces operational and payment pressure until resolved.
Shuttle Pharmaceuticals Holdings, Inc. reported that on September 11, 2025, director Joseph Tung resigned from its board of directors. The company stated that Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under the relevant SEC rules, indicating it was not tied to a reportable dispute over company operations, policies, or practices.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an initial Form 3 reporting that Adam V. Chambers is a director as of 09/08/2025. The filing lists Mr. Chambers' business address in Gaithersburg, MD and indicates he directly beneficially owns 0 shares of the issuer's common stock and holds no derivative securities. The form is an initial disclosure of a director's ownership and contains no reported holdings or exercisable awards.
Shuttle Pharmaceuticals Holdings, Inc. reported that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company’s revolving loan agreement dated February 28, 2025, and also a party to a consulting services agreement dated March 21, 2025. The Company states there are no family relationships between Mr. Chambers and any of its directors or executive officers, and, other than the loan and consulting agreements, he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. The filing also notes there were no arrangements or understandings by which he was appointed to the Board.
Shuttle Pharmaceuticals Holdings, Inc. reported that Steven Richards resigned as a director of the company on August 31, 2025. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals regarding its operations, policies, or practices. The report was signed on behalf of the company by Interim Chief Executive Officer Christopher Cooper.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
